Global expansion Besins Healthcare has expanded to 22 countries with a history of firsts and recent strategic acquisitions and partnerships, presenting opportunities to cross-sell Hormone Replacement Therapy (HRT) products, long-acting drug delivery technologies, and related reproductive health solutions across new markets.

Acquisition leverage The acquisition of UniD Manufacturing and ongoing investments in manufacturing capacity, including new factories in Spain, indicate readiness to scale production and support larger customer orders, which can be leveraged to win larger national and regional contracts.

Partnership channels Recent partnerships in Australia and ongoing relationships with healthcare professionals and institutions suggest a constructive pathway to expand access to menopausal therapies and gynecological products through distributor and healthcare network collaborations.

Portfolio modernization Investments in long-acting drug delivery technologies and expansion of hormone replacement therapy production signal opportunities to position Besins as a provider of innovative, patient-centric dosing forms and integrated solutions for clinics and hospitals.

Clinical and ESG engagement Active participation in industry events such as ESG congresses and a focus on sustainable, patient-centered care create openings for key account conversations with hospital systems, fertility clinics, and regional health authorities seeking reputable partners with a strong track record.